'Gwada Negative': Woman From Caribbean Island Only Carrier Of New Blood Type
A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed "Gwada negative," France's blood supply agency has announced.
The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on Friday.
"The EFS has just discovered the 48th blood group system in the world!" the agency said in a statement on the social network LinkedIn.
"This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT)."
The scientific association had until now recognised 47 blood group systems.
Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a "very unusual" antibody was first found in the patient in 2011.
However, resources at the time did not allow for further research, he added.
Scientists were finally able to unravel the mystery in 2019 thanks to "high-throughput DNA sequencing", which highlighted a genetic mutation, Peyrard said.
The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said.
This woman "is undoubtedly the only known case in the world," said the expert.
"She is the only person in the world who is compatible with herself," he said.
Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene.
The name "Gwada negative", which refers to the patient's origins and "sounds good in all languages", has been popular with the experts, said Peyrard.
The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing the discovery of new blood groups has accelerated in recent years.
Peyrard and colleagues are now hoping to find other people with the same blood group.
"Discovering new blood groups means offering patients with rare blood types a better level of care," the EFS said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
6 hours ago
- NDTV
'Gwada Negative': Woman From Caribbean Island Only Carrier Of New Blood Type
A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed "Gwada negative," France's blood supply agency has announced. The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on Friday. "The EFS has just discovered the 48th blood group system in the world!" the agency said in a statement on the social network LinkedIn. "This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT)." The scientific association had until now recognised 47 blood group systems. Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a "very unusual" antibody was first found in the patient in 2011. However, resources at the time did not allow for further research, he added. Scientists were finally able to unravel the mystery in 2019 thanks to "high-throughput DNA sequencing", which highlighted a genetic mutation, Peyrard said. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said. This woman "is undoubtedly the only known case in the world," said the expert. "She is the only person in the world who is compatible with herself," he said. Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene. The name "Gwada negative", which refers to the patient's origins and "sounds good in all languages", has been popular with the experts, said Peyrard. The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing the discovery of new blood groups has accelerated in recent years. Peyrard and colleagues are now hoping to find other people with the same blood group. "Discovering new blood groups means offering patients with rare blood types a better level of care," the EFS said.
Time of India
15 hours ago
- Time of India
EU reviews risk of abuse in some treatments for alcohol dependency
Bengaluru: The European Medicines Agency has begun a review of medicines to treat alcohol dependency that contain sodium oxybate , it said on Friday, following concerns of potential misuse or abuse. The regulator's review comes after the French medicines agency raised questions about the effectiveness of a generic drug with sodium oxybate to treat the condition, based on three studies, and warned of a possible risk of abuse due to its effects on the brain. The active ingredient attaches itself to receptors for the neurotransmitter GABA in the brain and the spinal cord, calming their activity. Sodium oxybate is sold as a syrup in Austria and as an oral solution in Italy for alcohol dependency under the name Alcover by privately owned D&A Pharma. In Europe, Jazz Pharmaceuticals' drug containing sodium oxybate, Xyrem, is approved to treat narcolepsy - a neurological disorder characterized by excessive daytime sleepiness and sudden muscle weakness. D&A Pharma and Jazz did not immediately respond to Reuters request for comment. Alcover is used to treat symptoms of alcohol withdrawal such as agitation, shaking and problems sleeping, either alone or as an add-on treatment. It is also used to support long-term abstinence from alcohol, along with counseling and social rehabilitation. The EMA's human medicines committee will assess the benefit-risk balance and evaluate measures to prevent misuse. Sodium oxybate is a form of GHB, or gamma hydroxybutyrate, which is a colorless and tasteless liquid. U.S. regulators have previously raised concerns about misuse of GHB as a party or "date-rape" drug due to its strong sedative effects.
Time of India
19 hours ago
- Time of India
A shot of hope
New HIV medicine is powerful – but can everyone afford it? A new medicine called lenacapavir has just been approved in the US to help stop people from getting HIV, the virus that causes AIDS. That's big news! Even though fewer people are getting HIV today than in the 1990s, around 13 lakh (1.3 million) people still get infected every year around the world. Lenacapavir is special because you only need two shots a year – not a pill every day like older medicines. That's great for people who forget daily pills or feel embarrassed taking them. And it's almost 100% effective at stopping HIV in adults and teens. But there's a big problem: the cost. In the US, it sells for over ₹23 lakh a year! Even rich countries find that hard to afford. The company that makes it, Gilead, is working with more than 100 poorer countries to help them make cheaper versions. Still, many African countries where HIV is most common may struggle to get it to the people who need it most. Scientists have been trying to create a proper HIV vaccine for decades, but HIV keeps mutating – changing too fast for one shot to work. New mRNA vaccines (like the ones used for Covid) are being tested, but funding cuts in the US have slowed down this research. That's why lenacapavir gives us hope. But hope only works if everyone, everywhere, can afford it. Facebook Twitter Linkedin Email Disclaimer Views expressed above are the author's own.
